Mayewell Capital, LLC

Mayewell Capital focuses on (1) engage in Pre-IPO biotech equity investments (2) facilitate in/out-licensing between US/EU and Asia-Pacific regions of approved generics, 505b2, innovative drugs, as well as assets still in development